WO2021007934A1 - 五谷虫浸酒制品在用于治疗糖尿病中的应用 - Google Patents
五谷虫浸酒制品在用于治疗糖尿病中的应用 Download PDFInfo
- Publication number
- WO2021007934A1 WO2021007934A1 PCT/CN2019/104318 CN2019104318W WO2021007934A1 WO 2021007934 A1 WO2021007934 A1 WO 2021007934A1 CN 2019104318 W CN2019104318 W CN 2019104318W WO 2021007934 A1 WO2021007934 A1 WO 2021007934A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- wine
- treatment
- grain
- composition
- insulin
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 36
- 241000736227 Lucilia sericata Species 0.000 title abstract 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 60
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 102000004877 Insulin Human genes 0.000 claims abstract description 30
- 108090001061 Insulin Proteins 0.000 claims abstract description 30
- 229940125396 insulin Drugs 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 26
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 230000001105 regulatory effect Effects 0.000 claims abstract description 9
- 241000238631 Hexapoda Species 0.000 claims description 51
- 238000011282 treatment Methods 0.000 claims description 48
- 235000014101 wine Nutrition 0.000 claims description 48
- 235000013339 cereals Nutrition 0.000 claims description 23
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 18
- 238000001802 infusion Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000000645 desinfectant Substances 0.000 claims description 12
- 238000007654 immersion Methods 0.000 claims description 9
- 239000011550 stock solution Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 235000020985 whole grains Nutrition 0.000 claims description 6
- 230000003203 everyday effect Effects 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 30
- 210000004369 blood Anatomy 0.000 abstract description 29
- 239000008280 blood Substances 0.000 abstract description 29
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 19
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract description 5
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract description 5
- 230000002441 reversible effect Effects 0.000 abstract description 3
- 238000002483 medication Methods 0.000 abstract description 2
- 230000003914 insulin secretion Effects 0.000 description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 17
- 230000003247 decreasing effect Effects 0.000 description 17
- 239000008103 glucose Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 238000012795 verification Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 10
- 238000007410 oral glucose tolerance test Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 210000004153 islets of langerhan Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241000405414 Rehmannia Species 0.000 description 2
- 241000218989 Trichosanthes Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 241000002026 Apamea apamiformis Species 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 241001113566 Hydrocharitaceae Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241001465805 Nymphalidae Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000020094 liqueur Nutrition 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940026314 red yeast rice Drugs 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the invention belongs to the technical field of food and medicine, and in particular relates to the application of a five-grain worm-soaked product in the treatment of diabetes.
- Insulin is a protein hormone. Insulin in the body is secreted by pancreatic ⁇ cells.
- Pancreatic islet cells are classified into the following types according to their function of secreting hormones:
- 2A cells ( ⁇ cells), which account for about 24% to 40% of pancreatic islet cells, secrete glucagon, which has the opposite effect of insulin and can increase blood sugar.
- 3D cells which account for about 6% to 15% of the total islet cells, secrete growth hormone inhibitory hormones.
- Diabetes In diabetic patients, due to various pathogenic factors such as viral infection, genetics, autoimmunity, etc., their pathophysiology is mainly due to the relative or absolute deficiency of insulin activity and the relative or absolute excess of glucagon activity, that is, B and A cells Caused by bilateral hormone dysfunction. Diabetes is a group of metabolic diseases characterized by hyperglycemia. Hyperglycemia is caused by defective insulin secretion or impaired biological effects, or both. The long-term high blood sugar in diabetes causes chronic damage and dysfunction of various tissues, especially eyes, kidneys, heart, blood vessels, and nerves. At present, there is no method in the world to restore and reverse the function of human insulin during the treatment of diabetes.
- Grain insects are the dried larvae of the nymphalidae or other related insects.
- the traditional Chinese medicine Wu Gu insects are also called rice worms, water nymphs, and Luo nymphs.
- the insects are salty, sweet, and cold in nature and pass through the spleen and stomach.
- the ingredients mainly contain protein, lysozyme, amino acids, and oils, with low toxicity, and have the functions of clearing heat and detoxification, eliminating accumulation and causing stagnation. It is recorded in "Compendium of Materia Medica” that it can be used to treat infantile malnutrition, malnutrition, fever, delirium, dysentery and vomiting. Therefore, the effective ingredients in the worms not only have antibacterial and antiviral effects, but also have antiparasitic, antioxidant, anti-aging, and anti-tumor effects.
- patent CN107375825A discloses a medicine for the treatment of diabetes, which is composed of edible alkali, rat woman, ant, grain insect, mulberry leaf, trichosanthes, gypsum, rehmannia, rehmannia, medlar, mulberry, ginger, Red ginseng, American ginseng, pueraria lobata root, etc. are prepared according to a certain weight ratio.
- the medicine of the present invention has the advantages of eliminating dampness and heat, dissolving food stagnation, invigorating kidney and essence, relaxing muscles and collaterals, relieving muscles and clearing heat, promoting body fluid and quenching thirst, invigorating lung yin, and clearing deficiency and fire. Function, used to treat diabetes with quick effect, good curative effect and no recurrence.
- the grain insects used in the composition play a role in clearing heat and eliminating stagnation, and are a ministerial medicine.
- Patent CN102335241A describes a medicine for the treatment of diabetes and hyperlipidemia, which is prepared from the following raw materials by weight: 6-10 parts of raw rhubarb, 3-10 parts of leech, 10-30 parts of grain insects, 10 parts of red yeast rice -30 servings, 10-15 servings of schisandra.
- the medicinal effect is long-lasting and the curative effect is good.
- the grain insects used in the composition are also added by using its salty cold to enter the spleen and stomach meridian, eliminate stagnation and clear heat, and have obvious lipid-lowering effects.
- Patent CN108404088A describes a medicine for the treatment of type 2 diabetes, which is composed of the following raw materials in parts by weight: 30-80 parts of dried ginger, 150-220 parts of coptis, 150-220 parts of scutellaria, 20-45 parts of American ginseng, and trichosanthes 150-220 servings and 150-220 servings of grain insects.
- TCM treatment clearing heat and reducing turbidity, replenishing qi and nourishing yin, it is used to treat the symptoms of thirst, liking for drinking, fatigue, lack of energy and lack of energy due to deficiency of both qi and yin. It is especially suitable for the treatment of qi and yin deficiency.
- Type 2 diabetes with symptoms such as thirst, preference for drinking, fatigue, lack of breath and lazy speech.
- the purpose of the present invention is to provide an application of a five-grain insect wine-infused product in the treatment of diabetes, specifically the application of a five-grain insect wine-infused product in preparing a composition for treating diabetes or a composition for regulating insulin levels.
- the present invention provides an application of a five-grain worm-soaked wine product for preparing a composition for treating diabetes.
- the present invention provides an application of a five-grain worm infusion product in preparing a composition for regulating insulin levels.
- the composition includes any one of medicines, health products, and foods.
- the preparation method of the five-grain insect wine product includes the following steps:
- step B2 Soak and disinfect the whole worms after processing in step B1, then rinse and drain;
- the disinfectant used in the immersion disinfection is a mixture of water and peracetic acid disinfection stock solution; more preferably, the immersion time is 10 minutes, and the volume ratio of water and peracetic acid disinfection stock solution is 1:400 .
- the weight ratio of the whole worm and the wine is 0.2:0.8 to 0.4:0.6; the sealing time is more than 2 months.
- the wine is pure grain wine with an alcohol content of 55°-70°.
- the dosage form made by the Wu Gu Chong includes any one of capsules, tablets, pills, powders, compound granules, health wines, oral liquids or freeze-dried powders.
- the present invention also provides a method for treating diabetes based on the aforementioned composition, which includes the following steps:
- each course of treatment is three months; the treatment method of each course of treatment is: taking a composition containing grains and insects infusion products, taking it every day The dosage of the five-grain insect wine soaked product in the composition is 1500mg-15g.
- the present invention also provides a method for regulating insulin levels based on the aforementioned composition, which includes the following steps:
- each course of treatment is three months; the treatment method of each course of treatment is: taking a composition containing grains and insects infusion products, taking it every day The dosage of the five-grain insect wine product in the composition is 1500mg-15g.
- the present invention has the following beneficial effects:
- the five-grain insect wine infusion product of the present invention is a natural product, and the effective ingredient of the five-grain insect wine product is the whole insect. Modern medical research has proved that the five-grain insect contains protein, fat, chitosan, and antibacterial peptides. A variety of amino acids.
- the grain worm freeze-dried powder of the present invention includes all the effective components of grain worm whole worm, and the grain worm extract is mainly composed of fatty acids and/or proteins, polypeptides, amino acids and the like. Studies have found that five-grain worm-infused wine products can more effectively eliminate human insulin resistance and improve human insulin sensitivity.
- OGTT glucose tolerance
- the five-grain insect product is made into a medicine, which is convenient to carry and take, and the clinical effective rate reaches 98%.
- the patient has been discontinued and observed for more than five years after conventional treatment. The condition is stable and the blood sugar is normal.
- Figure 1 is the sugar tolerance curve of the first verification example of the present invention.
- Figure 2 is the insulin release curve of verification example 1 of the present invention.
- Figure 3 is the sugar tolerance curve of the second verification example of the present invention.
- Figure 4 is the insulin release curve of the second verification example of the present invention.
- Fig. 6 is the sugar tolerance curve of verification example 4 of the present invention.
- Fig. 7 is the insulin release curve of verification example 4 of the present invention.
- the following example provides an application of a five-grain worm-infused wine product for preparing a composition for treating diabetes.
- the following example provides an application of a five-grain insect wine soaked product in the preparation of a composition for regulating insulin levels.
- the composition includes any one of medicines, health products and foods.
- the preparation method of the five-grain-worm-soaked wine product includes the following steps:
- step B2 Soak and disinfect the whole worms after processing in step B1, then rinse and drain;
- the disinfectant used in the immersion disinfection is a mixture of water and peracetic acid disinfectant stock solution, and the immersion time is 10 minutes; more preferably, the volume ratio of water to peracetic acid disinfectant stock solution is 1:400.
- step B3 the weight ratio of the whole worm and the wine is 0.2:0.8 to 0.4:0.6; the sealing time is more than 2 months.
- the wine is pure grain wine with an alcohol content of 55°-70°.
- the dosage form of the five-grain insect wine-infused product includes any one of capsules, tablets, pills, powders, compound granules, health wine, oral liquid or freeze-dried powder.
- the following examples also provide a method for treating diabetes and regulating insulin levels based on the aforementioned composition, which includes the following steps:
- each course of treatment is three months; the treatment method of each course of treatment is: taking a composition containing grains and insects infusion products, taking it every day The dosage of the five-grain insect wine soaked product in the composition is 1500mg-15g.
- the present embodiment provides a method for preparing the dried grain insect powder, which includes the following steps:
- step A2 Soak and disinfect the whole grain worms treated in step A1, then rinse and drain;
- the freeze-dried whole worms are pulverized at low temperature to obtain dry powder of worms.
- the disinfectant used in the immersion disinfection is a mixture of water and peracetic acid disinfectant stock solution, and the immersion time is 10 minutes; the volume ratio of water and peracetic acid disinfectant stock solution is 1:400.
- step A3 the low-temperature freezing temperature is -20-50°C, and the freezing time is 24h.
- This embodiment provides a preparation method of a five-grain insect wine soaked product, including the following steps:
- step B2 Soak and disinfect the whole worms after processing in step B1, then rinse and drain;
- the disinfectant used in the immersion disinfection is a mixture of water and peracetic acid disinfectant stock solution, and the immersion time is 10 minutes; the volume ratio of water and peracetic acid disinfectant stock solution is 1:400.
- step B3 the weight ratio of the whole worm and the wine is 0.2:0.8 ⁇ 0.4:0.6; the storage time is more than 2 months; the wine is pure grain with an alcohol content of 55° ⁇ 70° liqueur.
- Verification example 1 Combination treatment with Wu Gu insect freeze-dried powder and Wu Gu insect wine soaking
- the treatment plan is: three times a day, 1500 mg of Wu Gu Chong dry powder capsule prepared in Example 1 is taken before meals; 2000 mg of Wu Gu Chong wine infusion product prepared in Example 2 is taken before going to bed.
- the sugar tolerance peak reverses and moves forward, from the initial 120 minutes to 60 minutes.
- the 60-minute insulin release and fasting times increased from the initial 3.52 times to 9.22 times (5-10 times the normal value), and the peak insulin release increased from the initial 5.01 times to 11.16 times (5-10 times the normal value).
- the treatment plan is: three times a day, 1500 mg of Wu Gu Chong dry powder capsule prepared in Example 1 is taken before meals; 2000 mg of Wu Gu Chong wine infusion product prepared in Example 2 is taken before going to bed.
- Insulin release decreased by 55.94.27% in 60 minutes and blood glucose decreased by 2.64mmol/L.
- Insulin release decreased by 52.34% in 180 minutes and blood sugar decreased by 5.30mmol/L.
- Validation example three combined treatment with Wu Gu insect freeze-dried powder and Wu Gu insect wine soaking
- Lu XX Gender Male Age: 36 years old 2019/3/14 Started treatment for 71 days and stopped taking all western medicines.
- the treatment plan is: three times a day, 1500 mg of Wu Gu Chong dry powder capsule prepared in Example 1 is taken before meals; 2000 mg of Wu Gu Chong wine infusion product prepared in Example 2 is taken before going to bed.
- the ratio of peak insulin to fasting insulin increased from 4.66 times to 8.09 times, an increase of 3.43 times.
- the peak insulin increased from 23.3 ⁇ IU/mL to 27.74 ⁇ IU/mL, an increase of 19.06%.
- Verification Example 4 Treatment with five-grain insects soaked in wine products alone
- the treatment plan is: twice a day, 2000 mg of the five-grain insect wine soaked product prepared in Example 2 each time.
- the glucose tolerance peak reverses and moves forward, from the initial 120 minutes to 60 minutes, which is in line with the normal glucose tolerance.
- Insulin release decreased by 74.08% in 120 minutes and blood sugar decreased by 9.05mmol/L.
- Insulin 30 minutes insulin release and recovery ratio increased from 1.67 times to 2.62 times the initial.
- 2000mg of the five-grain worm infusion product prepared in Example 2 is equivalent to the dose of 500mg of the five-grain worm dry powder prepared in Example 1. From the verification example 4, the patient's consumption of the five-grain worm infusion product is far lower than the above three cases The effect is also obvious, so the five-grain insect soaked wine product is actually better than the five-grain insect powder for diabetic patients.
- Wu Gu Chong is used to treat diabetic patients. After a period of treatment, comparing the two OGTT measurements before and after the patient, it is medically proven that the patient's insulin resistance can be repaired and insulin sensitivity improved. After stopping all medications (2-5 years) The patient's blood sugar control can be achieved excellent, the glycosylated hemoglobin is less than 6.3, so far there has been no rebound.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Animal Husbandry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
项目 | 0分钟 | 30分钟 | 60分钟 | 120分钟 | 180分钟 | |
服药前 | 血糖值mmol/L 0 | 8.41 | 13.00 | 16.72 | 17.96 | 11.87 |
胰岛素μIU/mL 0 | 10.85 | 45.00 | 80.16 | 38.31 | 21.13 | |
服药后 | 血糖值mmol/L 1 | 6.52 | 11.83 | 14.08 | 12.66 | 4.75 |
胰岛素μIU/mL 1 | 6.72 | 24.18 | 35.32 | 47.81 | 10.07 |
项目 | 0分钟 | 30分钟 | 60分钟 | 120分钟 | 180分钟 | |
服药前 | 胰岛素μIU/mL 0 | 5.00 | 8.00 | 12.60 | 23.30 | 15.60 |
服药后 | 胰岛素μIU/mL 1 | 3.43 | 10.01 | 27.74 | 26.22 | 21.97 |
Claims (10)
- 一种五谷虫浸酒制品在用于制备治疗糖尿病的组合物中的应用。
- 一种五谷虫浸酒制品在制备调节胰岛素水平的组合物中的应用。
- 根据权利要求1或2所述的应用,其特征在于,所述组合物包括药品、保健品、食品中的任一种。
- 根据权利要求1或2所述的应用,其特征在于,所述五谷虫浸酒制品制成的剂型包括胶囊剂、片剂、丸剂、散剂、复方颗粒剂、保健酒、口服液或冻干粉中的任一种。
- 根据权利要求1或2所述的应用,其特征在于,所述五谷虫浸酒制品的制备步骤包括:B1、将收集的五谷虫全虫清洗、冲刷,把表面的脏污去除干净;B2、将步骤B1处理后的五谷虫全虫进行浸泡消毒,然后冲洗,沥干;B3、将沥干后的五谷虫全虫投入酒中,封存;B4、将封存后的五谷虫全虫取出,进行低温超细粉碎,即得。
- 根据权利要求5所述的应用,其特征在于,步骤B2中,所述浸泡消毒采用的消毒液为水和过氧乙酸消毒原液的混合物。
- 根据权利要求5所述的应用,其特征在于,步骤B3中,所述五谷虫全虫与酒的重量份比例为:0.2∶0.8~0.4:0.6;所述封存时间为2个月以上。
- 根据权利要求5所述的应用,其特征在于,步骤B3中,所述酒为酒精度55°~70°的纯粮食酒。
- 一种基于权利要求1所述的组合物治疗糖尿病的方法,其特征在于,包括以下步骤:经检测后,根据糖尿病的患病程度,进行1-6个疗程治疗,每个疗程为三个月;所述每个疗程的治疗方法为:服用包含五谷虫浸酒制品的组合物,每天服用的组合物中五谷虫浸酒制品的剂量为1500mg-15g。
- 一种基于权利要求1所述的组合物调节胰岛素水平的方法,其特征在于,包括以下步骤:经检测后,根据糖尿病的患病程度,进行1-6个疗程治疗,每个疗程为三个月;所述每个疗程的治疗方法为:服用包含五谷虫浸酒制品的组合物,每天服用的组合物中五谷虫浸酒制品的剂量为1500mg-15g。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910642598.7 | 2019-07-16 | ||
CN201910642598.7A CN110327373B (zh) | 2019-07-16 | 2019-07-16 | 五谷虫浸酒制品在用于治疗糖尿病中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021007934A1 true WO2021007934A1 (zh) | 2021-01-21 |
Family
ID=68145485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/104318 WO2021007934A1 (zh) | 2019-07-16 | 2019-09-04 | 五谷虫浸酒制品在用于治疗糖尿病中的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110327373B (zh) |
WO (1) | WO2021007934A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110302213A (zh) * | 2019-07-16 | 2019-10-08 | 华祥荣 | 五谷虫在用于治疗糖尿病中的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102335241B (zh) * | 2011-10-12 | 2013-06-05 | 郭聚忠 | 一种治疗糖尿病合并高脂血症的药物及其制备方法 |
-
2019
- 2019-07-16 CN CN201910642598.7A patent/CN110327373B/zh active Active
- 2019-09-04 WO PCT/CN2019/104318 patent/WO2021007934A1/zh active Application Filing
Non-Patent Citations (2)
Title |
---|
CHEN, LINJUN ET AL.: "Study on the Determination of Nutrient Contents of Fly Maggot Powder and the Effect of Flyblow Chitosan on Anti-oxidant Function in Experimental Diabetic Rats", JOURNAL OF MEDICAL RESEARCH, vol. 40, no. 04, 30 April 2011 (2011-04-30), ISSN: 1673-548X, DOI: 9120311 * |
HU, MEIBIAN ET AL.: "Research on Quality Standards of Wuguchong", PHARMACY AND CLINICS OF CHINESE MATERIA MEDICA, vol. 7, no. 03, 30 June 2016 (2016-06-30), ISSN: 1674-926X, DOI: 9120312 * |
Also Published As
Publication number | Publication date |
---|---|
CN110327373B (zh) | 2021-03-16 |
CN110327373A (zh) | 2019-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102526478B (zh) | 一种增强免疫力、降血糖功能的保健药物配方 | |
CN1310668C (zh) | 治疗糖尿病的药物及其制备方法 | |
CN106389757B (zh) | 一种治疗糖尿病肾病的药物组合物及其制备方法和用途 | |
WO2021007934A1 (zh) | 五谷虫浸酒制品在用于治疗糖尿病中的应用 | |
WO2021007933A1 (zh) | 五谷虫在用于治疗糖尿病中的应用 | |
CN104623607B (zh) | 一种治疗风湿类风湿病的中药组合物 | |
CN103055176B (zh) | 一种治疗糖尿病的中药及其制备方法 | |
CN113041300B (zh) | 糖肾祛湿方及其应用 | |
CN104324261A (zh) | 治疗高血糖的药物组合物及其制备方法 | |
CN104095930B (zh) | 一种治疗胃出血的中药药物 | |
CN102614359A (zh) | 一种治疗糖尿病的中药制剂及制备方法 | |
CN112438397A (zh) | 一种供高血糖人群食用的药膳 | |
CN102114185B (zh) | 一种治疗2型糖尿病胰岛素抵抗的药物 | |
CN102526248B (zh) | 一种治疗糖尿病伤口溃烂并可持续降血糖的中药组合物 | |
CN116159102B (zh) | 一种治疗餐后不适综合征的中药组合物及其制备方法和用途 | |
CN104740345B (zh) | 治疗糖尿病的中药组合物及其制备方法 | |
CN104922445B (zh) | 一种具有治疗心力衰竭作用的中药复方组合物及其制备方法与应用 | |
CN107551192A (zh) | 一种具有治疗慢性肾脏病的中药复方组合物及其制备方法与应用 | |
CN113304234B (zh) | 一种用于治疗慢性肾衰竭的中药组合物 | |
LU501408B1 (en) | A coptis chinensis and atractlodis rhizoma based prescription for treating diabetes | |
CN107137489A (zh) | 一种用于降血糖的中药组合物及其制备方法和应用 | |
CN101732563A (zh) | 来自槐耳菌质、枸杞子和黄精的组合物的用途 | |
CN105999174A (zh) | 一种治疗糖尿病的中药及其制备方法 | |
CN101124990A (zh) | 葎草在制备抗疲劳、耐缺氧药物或保健食品中的新用途 | |
CN104083673A (zh) | 一种治疗慢性肾小球肾炎的中药组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19937466 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19937466 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19937466 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC |